Addition of rituximab to the CHOP regimen has no benefit in patients with primary extranodal diffuse large B-cell lymphoma

BACKGROUND: The addition of rituximab to cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy (R-CHOP) has significantly improved clinical outcomes for patients with diffuse large B-cell lymphoma (DLBCL). However, new predictors of patient response to R-CHOP have not been e...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Jang, Geundoo, Yoon, Dok Hyun, Kim, Shin, Lee, Dae Ho, Lee, Sang-wook, Huh, Jooryung, Suh, Cheolwon
Format: Artigo
Idioma:Inglês
Publicat: Korean Society of Hematology; Korean Society of Blood and Marrow Transplantation; Korean Society of Pediatric Hematology-Oncology; Korean Society on Thrombosis and Hemostasis 2011
Matèries:
Original Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3128890/
https://ncbi.nlm.nih.gov/pubmed/21747882
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.5045/kjh.2011.46.2.103
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars